In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Calcitonin-salmon | Natural fragment Teriparatide (PTH 1-34) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Natural fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 661 | 2,709 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 58 (58 in people) | 209 (168 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 18 · 1 active7 more mention it but do not test it | 168 · 15 active30 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Calcitonin salmon nasal spray says: “Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Calcitonin-salmon | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletal | 361346411 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Forteo says: “The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients”
2,2281286913263
| Adverse eventsWhole body | 4242 | 16313726 |
|---|
| PainNervous system and cognition | 5252 | 6262 |
|---|
| PharmacokineticsRespiratory | 4949 | 30273 |
|---|
| Exercise and physical functionMusculoskeletal | 2828 | 1818 |
|---|
| Electrolyte balanceKidney and urinary | 1515 | 3030 |
|---|
| Receptor activity and mechanismPharmacology | 331221 | 46151516 |
|---|
| Kidney functionKidney and urinary | 66 | 27243 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1313 | 1212 |
|---|
| Quality of lifeWhole body | 44 | 1313 |
|---|
| Glycemic controlMetabolic and weight | 651 | 44 |
|---|
| MortalityWhole body | 22 | 312 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 18 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Nordic Bioscience A/S1,030 participantsJun 2008 to Jun 2011
Osteoarthritis
Tarsa Therapeutics, Inc.565 participantsJun 2009 to Feb 2011
Osteoporosis, Postmenopausal
Eli Lilly and Company364 participantsDec 2006 to Jul 2008
Osteoporosis
7 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 168 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Eli Lilly and Company1,366 participantsOct 2012 to Jul 2016
Postmenopausal Osteoporosis
Eli Lilly and Company712 participantsJun 2006 to Jun 2010
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
30 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Calcitonin-salmon | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | 3% Lumbar BMD change from baseline Dose studied: 200 IU daily, 1 month on-1 month off1 yearn = 912005 | 7.2% Lumbar spine BMD change Dose studied: 20 microg once daily18 monthsn = 4282007 |
3%
Lumbar BMD change from baseline
Dose studied: 200 IU daily, 1 month on-1 month off1 yearn = 912005
7.2%
Lumbar spine BMD change
Dose studied: 20 microg once daily18 monthsn = 4282007
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Calcitonin-salmon | Teriparatide (PTH 1-34) |
|---|---|---|
| PainMusculoskeletalCompared as: difference from placebo, in % | No comparable result 21 randomized-trial results measure it in another way or another unit. | −31% Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size. |
| Exercise and physical functionMusculoskeletalCompared as: value in the arm that got the peptide, in s | No comparable result 16 randomized-trial results measure it in another way or another unit. | −3.2 to −5.9 s TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks Dose studied: 20 μg every day78 weeksn = 1712017 |
|---|
| Electrolyte balanceEndocrine and hormonesCompared as: value in the arm that got the peptide, in of 13 patients | No comparable result 3 randomized-trial results measure it in another way or another unit. | 10 of 13 patients Stopped calcium carbonate supplements · teriparatide group, 1 month after discharge Control group, 1 month after discharge: 5 of 13 patients Dose studied: 20 mcg every 12 hoursuntil dischargen = 262016 |
|---|
| Adverse eventsMusculoskeletalCompared as: value in the arm that got the peptide, in % | No comparable result 10 randomized-trial results measure it in another way or another unit. | 10% Nasopharyngitis Dose studied: 20 μg once daily12 monthsn = 4322017 |
|---|
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 13% Nausea rate Dose studied: 20 g/day as printed6 monthsn = 1042006 |
|---|
No comparable result
21 randomized-trial results measure it in another way or another unit.
−31%
Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size.
Dose studied: 20 microgmedian 19 monthsn = 1,0852005
No comparable result
16 randomized-trial results measure it in another way or another unit.
−3.2 to −5.9 s
TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks
Dose studied: 20 μg every day78 weeksn = 1712017
No comparable result
3 randomized-trial results measure it in another way or another unit.
10 of 13 patients
Stopped calcium carbonate supplements · teriparatide group, 1 month after discharge
Control group, 1 month after discharge: 5 of 13 patients
Dose studied: 20 mcg every 12 hoursuntil dischargen = 262016
No comparable result
10 randomized-trial results measure it in another way or another unit.
10%
Nasopharyngitis
Dose studied: 20 μg once daily12 monthsn = 4322017
No comparable result
2 randomized-trial results measure it in another way or another unit.
13%
Nausea rate
Dose studied: 20 g/day as printed6 monthsn = 1042006